Before we jump into a new week, let's have a look at what happened last week on the IP blogs...
Sunday already?! |
Patents
Regulation (EU) 2019/933, amending the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products (the SPC Regulation) was published in the Official Journal of the European Union on 11 June 2019 and thus came into effect on 1 July 2019. The amended Regulation establishes the so-called “SPC waiver”, that excludes certain acts, which would otherwise require the consent of the SPC holder, from protection conferred by the SPC, if the prescribed conditions are met. Kluwer Patent Blog reported on the practical implementation of the requirements of the Regulation.
Must a plaintiff investigate a
patent’s validity prior to suing for infringement? This question was raised in
the case of WPEM LLC v. SOTI Inc. PatentlyO
reported on the finding of the Court.
On December 29, the United States
Court of Appeals for the Federal Circuit (CAFC) affirmed a district court’s
decision dismissing Simio’s patent infringement action against FlexSim Software
Products (FlexSim) and finding Simio’s claims patent ineligible under 35 U.S.C.
§ 101 (Simio
v. FlexSim Software Products, Inc.). IPWatchdog
reported on the case.
Copyright
In a great start to the Sci-Hub
litigation, Justice Midha at the Delhi High Court repeatedly pointed out that
the issues in this case involved ‘a matter of public importance’, while saying
he would not want to pass any orders in the law suit without hearing the
various parties that wanted to get their views heard in the case, for the
interim application as well as the suit. SpicyIP
highlighted some of the important parts of the case.
Designs
MARQUES reported on The
European Commission’s report on the evaluation of EU legislation on design
protection. The report is the result of an extensive study, including a
consultation in which MARQUES took part.
Other: Covid-19
MARQUES
published a summary of an Early Warning Notification regarding vaccine-related
crime during the COVID-19 pandemic, which was recently published by EUROPOL. The
notification warns that organised crime groups may be preparing to produce
counterfeit vaccines, spread disinformation about vaccines and illegally refill
vials. It also notes that some dark web markets already feature adverts for
fake COVID-19 vaccines.
No comments:
All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.
It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.
Learn more here: http://ipkitten.blogspot.com/p/want-to-complain.html